Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease
| العنوان: | Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease |
|---|---|
| المؤلفون: | Bjorn Andreasson, Peter L. Johansson, Federico Sackmann, Giovanni Barosi, Zhijian Xiao, Françoise Boyer, Ruben A. Mesa, Suzan Commandeur, Carlos Besses, Tiziano Barbui, Norman Maldonado, Maria Luisa Ferrari, Peter A. W. te Boekhorst, Francisco Cervantes, Jean-Jacques Kiladjian, Yue Zhang, Zhenya Senyak, Harry C. Schouten, Karin Bonatz, Konstanze Döhner, Dana Ranta, Zefeng Xu, Jan Samuelsson, Jean-Yves Cahn, Francesco Passamonti, Deepti Radia, Andreas Reiter, Sonja Zweegman, Xiujuan Sun, Alessandro Rambaldi, Ana Kerguelen Fuentes, Junqing Xu, Thomas Lehmann, Lydia Roy, Gabriel Etienne, Alessandro M. Vannucchi, Heidi E. Kosiorek, Jean Christophe Ianotto, Martin Griesshammer, Peihong Zhang, Robert Peter Gale, Heike L. Pahl, Gunnar Birgegård, Claire N. Harrison, Frank Stegelmann, Robyn M. Scherber, Pablo J. Muxi, Stefanie Slot, Dolores Hernández-Maraver, Amylou C. Dueck, Holly L. Geyer |
| المساهمون: | Hématologie -Immunologie -Cibles thérapeutiques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigations Cliniques, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Hematology, Ospedali Riuniti, Santé publique, vieillissement, qualité de vie et réadaptation des sujets fragiles - EA 3797 (SPVQVRSF), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA), Service de Médecine Physique Neurologique-Traumatologique [Reims], Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims)-Hôpital Sébastopol, Institut de pharmacologie et de biologie structurale (IPBS), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), Institut de cancérologie et d'hématologie, Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Réactions et Génie des Procédés (LRGP), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Department of Haematology, Division of Medicine, Institution for Medical Sciences, University Hospital, Laboratoire de Biologie Moléculaire et Cellulaire des Eucaryotes (LBMCE), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Institute of medicinal plant development, Chinese Academy of Medical Sciences, State Key Laboratory of Rare Resource Utilization, Changchun Institute of Applied Chemistry, Internal medicine, CCA - Evaluation of Cancer Care, Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF) |
| المصدر: | Journal of Clinical Oncology Journal of Clinical Oncology, 2016, 34 (2), pp.151-9. ⟨10.1200/JCO.2015.62.9337⟩ Geyer, H, Scherber, R, Kosiorek, H, Dueck, A C, Kiladjian, J-J, Xiao, Z, Slot, S, Zweegman, S, Sackmann, F, Kerguelen Fuentes, A, Hernandez-Maraver, D, Doehner, K, Harrison, C N, Radia, D, Muxi, P, Besses, C, Cervantes, F, Johansson, P L, Andreasson, B, Rambaldi, A, Barbui, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, J-C, Ranta, D, Roy, L, Cahn, J-Y, Maldonado, N, Barosi, G, Ferrari, M L, Gale, R P, Birgegard, G, Xu, Z, Zhang, Y, Sun, X, Xu, J, Zhang, P, te Boekhorst, P A W, Commandeur, S, Schouten, H, Pahl, H L, Griesshammer, M, Stegelmann, F, Lehmann, T, Senyak, Z, Vannucchi, A M, Passamonti, F, Samuelsson, J & Mesa, R A 2016, ' Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease ', Journal of Clinical Oncology, vol. 34, no. 2, pp. 151-+ . https://doi.org/10.1200/JCO.2015.62.9337 Journal of Clinical Oncology, 34(2), 151-+. American Society of Clinical Oncology Journal of Clinical Oncology, American Society of Clinical Oncology, 2016, 34 (2), pp.151-9. ⟨10.1200/JCO.2015.62.9337⟩ |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Male, Cancer Research, Conference Paper, very elderly, [SDV]Life Sciences [q-bio], thrombocytopenia, thrombocytosis, Disease, Severity of Illness Index, bone pain, 0302 clinical medicine, Polycythemia vera, Phlebotomy, 80 and over, Hydroxyurea, genetics, Prospective Studies, Prospective cohort study, abdominal discomfort, Polycythemia Vera, antineoplastic agent, Fatigue, Aged, 80 and over, Palpation, Symptomatic Profiles, Middle Aged, Prognosis, anemia, 3. Good health, Oncology, leukocytosis, priority journal, validation study, 030220 oncology & carcinogenesis, Female, prospective study, Adult, medicine.medical_specialty, Fever, Anemia, Pain, complication, Antineoplastic Agents, Sweating, 03 medical and health sciences, hemoglobin, hydroxyurea, Janus kinase, abdominal discomfort, adult, controlled study, disease duration, fatigue, fever, hemoglobin blood level, human, leukopenia, major clinical study, middle aged, night sweat, palpable splenomegaly, phlebotomy, polycythemia vera, pruritus, splenomegaly, symptom assessment, weight reduction, aged, antagonists and inhibitors, female, male, pain, palpation, prognosis, severity of illness index, sweating, very elderly, Adult, Aged, Humans, Janus Kinases, Pruritus, Splenomegaly, Weight Loss, Internal medicine, Severity of illness, medicine, Myeloproliferative neoplasm, Thrombocytosis, business.industry, medicine.disease, Surgery, business, Janus kinase, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030215 immunology |
| الوصف: | Purpose Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness of JAK inhibitor therapy in patients with PV patients who have a history of prior hydroxyurea (HU) use (including resistance or intolerance), phlebotomy requirements, and palpable splenomegaly. We aimed to determine how these features contribute alone and in aggregate to the PV symptom burden. Patients and Methods Through prospective evaluation of 1,334 patients with PV who had characterized symptom burden, we assessed patient demographics, laboratory data, and the presence of splenomegaly by disease feature (ie, known HU use, known phlebotomy requirements, splenomegaly). Results The presence of each feature in itself is associated with a moderately high symptom burden (MPN symptom assessment form [SAF] total symptom score [TSS] range, 27.7 to 29.2) that persists independent of PV risk category. In addition, symptoms incrementally increase in severity with the addition of other features. Patients with PV who had all three features (PV-HUPS) faced the highest total score (MPN-SAF TSS, 32.5) but had similar individual symptom scores to patients with known HU use (PV-HU), known phlebotomy (PV-P), and splenomegaly (PV-S). Conclusion The results of this study suggest that patients with PV who have any one of the features in question (known HU use, known phlebotomy, or splenomegaly) have significant PV-associated symptoms. Furthermore, it demonstrates that many PV symptoms remain severe independent of the number of features present. |
| تدمد: | 1527-7755 0732-183X |
| DOI: | 10.1200/JCO.2015.62.9337⟩ |
| DOI: | 10.1200/JCO.2015.62.9337 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbfb1c4fab06e255a5f72c8a997b3190 https://pubmed.ncbi.nlm.nih.gov/26598745 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....cbfb1c4fab06e255a5f72c8a997b3190 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|---|
| DOI: | 10.1200/JCO.2015.62.9337⟩ |